Joel M. M. Trugman, MD

Associate VP, Clinical Development Neuroscience
AbbVie
Madison, New Jersey

Disclosure information not submitted.

Presentation(s):

• Efficacy of Ubrogepant for the Treatment of Migraine Symptoms During the Prodrome (Premonitory Phase): Results From the PRODROME Trial

  POSTER ABSTRACT

• Improvement in Patient-Reported Outcomes When Ubrogepant Is Administered During the Migraine Prodrome (Premonitory Phase): Results From the PRODROME Trial

  POSTER ABSTRACT

• Ubrogepant for the Acute Treatment of Migraine When Administered During the Prodrome (Premonitory Phase): Results From a Phase 3, Randomized, Double-blind, Placebo-Controlled, Crossover Study

  POSTER ABSTRACT